US7207951036 - Common Stock
PIERIS PHARMACEUTICALS INC
NASDAQ:PIRS (5/3/2024, 7:12:24 PM)
11.08
-0.16 (-1.42%)
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 127 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics.
PIERIS PHARMACEUTICALS INC
225 Franklin Street, 26th Floor
Boston MASSACHUSETTS 02109
P: 18572468998
CEO: Stephen S. Yoder
Employees: 127
Website: https://www.pieris.com/
Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!
It's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning!
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.
Here you can normally see the latest stock twits on PIRS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: